• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    New phosphinylalkanoyl prolines which have the general formula <IMAGE> wherein R1 is lower alkyl, phenyl or phenyl-lower alkyl; R2 is hydrogen, phenyl-lower alkyl or a metal ion; R3 is hydrogen or lower alkyl; R4 is hydrogen, lower alkyl, phenyl-lower alkyl or a metal ion; and N IS 0 OR 1, ARE USEFUL AS HYPOTENSIVE AGENTS.
    公开号:SU988194A3
    申请号:SU792835388
    申请日:1979-10-22
    公开日:1983-01-07
    发明作者:Вильям Петрилло Младший Эдвард
    申请人:Е.Р.Сквибб Энд Санз,Инк (Фирма)；
    IPC主号:
    专利说明:

    (5) METHOD FOR PRODUCING PHOSPHINYLALCANOILPROLINES
    The invention relates to the chemistry of organophosphorus compounds, namely to a method for the preparation of new phosphinylalkanoyl prolines of the general formula for rCO-lf-L COOK 5 i-P-Oif, where R is lower alkyl, phenyl, pheny is lower alkyl; R2 and Ra are hydrogen or benzyl, which can be used as blood pressure lowering agents. A known method for producing proline esters by reacting a new compound of the general formula HN- with an acid of the form X-CH-CH-SorN at room temperature fl}. There is also known a method for producing proline false esters by the interaction of a proline compound of the formula HN-IGOOH with a dicarboxylic acid monoester f 2. However, the compounds of general formula (I) and the method for their preparation are not described in the literature. The purpose of the invention is the development. available method for producing compounds of general formula (I). This goal is achieved by the fact that according to the method of obtaining phosphinyl-alkanoyl-prolines of the general formula. (I), a proline compound of the general formula COOKs, 398 where RO, hydrogen or benzyl, is reacted: with phosphinyl acetic acid of the general formula Bt-P-CH2- (iooii, OKg where R is lower alkyl, phenyl phenyl lower alkyl, Rr is hydrogen or benzyl, at 0 ° C in the presence of a condensation catalyst, 1,1-carbonyldiimidazole in acetonitrile with a release of cent. of the left product of the formula (|), where R is benzyl, or by catalytic reduction with hydrogen in addition as a result of palladium on carbon black in an environment of absolute methanol or ethanol at a hydrogen pressure of 1 atm to produce a compound of general formula (I), where Rg is hydrogen.; Compounds of general formula (I) are angiotensin-converting enzyme inhibitors and are used as blood pressure lowering agents, in particular for lowering renin angiotensin, associated with elevated blood pressure, such as cardiovascular hypertension or malignant hypertension. When administering a formulation containing one or the combination of angiotensin converting enzyme inhibitors to mammals with elevated blood pressure, it interferes with the sequence of renin-angiotensin-angiotensin I-angiotensin I action and the elevated pressure decreases or is alleviated. One dose, preferably divided into 2- to daily doses, is provided at the rate of 30-300 mg per kilogram of body weight per day, and preferably 10-100 mg per kg of body weight per day, to lower the blood pressure. I The composition is prescribed subcutaneously, intramuscularly, intravenously, intraperitoneally, but it can also be administered orally with a dose of 10-1000 mg (preferably 10-100 mg) per 1 kg of weight per day. For parenteral administration, sterile solutions or suspensions may be used. About 100-500 mg of a compound or compounds of formula I can be combined with a physiologically acceptable solvent, carrier, binder, preservative, stabilizer, seasoning, etc. with the usual dosage. The amount of active substance is chosen so as to provide a dose within the specified limits. Example. 1- Hydroxy- (2-phenylethyl) (1usphenyl acetyl-cL -prolin. A, Solution tl hydroxy- {2g-phenylethyl) phosphinyl acetic acid (9.1 g 0.04 mol) and acetyl chloride (1 ml) in methanol (100 ml) are refluxed the day before. The reaction mixture is then concentrated in vacuo to give 9.63 g of the product, hydroxy- methyl ester (2-phenylethylphosphinyl acetic acid. C.) A solution of 3-benzyl-1-p-tolyltriazene cooled to 0 ° C (8.91 g, 0 , 0 mol) in diethyl ether (350 ml) is immediately treated with a solution of hydroxide- (2-phenylethyl) phosphinyl acetic acid methyl ester (9.63 g, o, 04 mol) in ethyl acetate (15 ml). The reaction mixture is then stirred at room temperature. The ethereal solution is then extracted with hydrochloric acid and brine, dried over magnesium sulfate and center in vacuo. The residue is chromatographed on silica gel (si lie ARCC-7) (500 ml), washed with a mixture of hexane / ethyl acetate, to obtain 6 g of the product of methyl ester 2-phenylethyl (phenylmethoxyphosphinyl acetic acid (TLC: silica gel hexane / ethyl acetate (j: (A),), 15, UV-visualization.) C. A solution of (2-phenylethyl) - (phenylmethoxy) -phosphinyl acetic acid methyl ester (5.62 g, 0.017 mol) and 1N sodium hydroxide (17.1 ml, 0.017 mol) in methanol (30 ml) is stirred at room temperature the day before. The reaction mixture was concentrated in vacuo. The residue is dissolved in water and washed with ether. The aqueous layer is then acidified with a solution of potassium bisulfate and extracted several times with ethyl acetate. The combined ethyl acetate extracts are dried over magnesium sulfate and concentrated in vacuo to give 5.6 g of the product (2-phenylethyl) - (phenylmethoxy) phosphinyl 3 acetic acid. Electrophoresis: 200 V, 20 min, 0.1 M MH4HCO3 +, 5 cm, the only spot visualized with carboxyl reagent. 598 D, Diimidazolecarbonyl (2.86 g, 0, bl8 mol) was dissolved in acetonitrile (200 ml), cooled in an ice bath, and treated with 2-phenyl. ethyl) - (phenylmethoxy) phosphinyl 3-: hydrochloric acid (5.6 g, 0.018 mol) in acetonitrile (15 ml). The mixture is stirred for 1 hour at 0 ° C, then immediately treated with a solution of phenylmethyl ester o-proline (3.6 g, (o, 018 mol) in acetonitrile (t5 ml). The reaction mixture is stirred for 1 h and then left overnight at room temperature. The reaction mixture is concentrated in vacuo, the residue is dissolved in ethyl acetate and washed with potassium bisulfate and 5% sodium bicarbonate. (The ethyl acetate layer is dried over sodium sulfate and concentrated in vacuo to give 8 g of a crude product. This product is chromatographed on silica gel (si lie AR SS-y) (250 m), washing out the mixture Dichloromethane / ethyl acetate gave 7.11 g of 1- (2-phenylethyl) - (phenylmethoxyphosphinyl acetyl-oi-proline phenylmethyl ester (TLC, silica gel, ethyl acetate, Hg, 0.2, UV-visualization)) 7.11 g of product. A mixture of phenylmethyl ether 11: (2g phenylethyl) - (phenylmethoxy) phosphinyl acetyl-oC-proline (7.11 g 0.01 mol) and 10 palladium on carbon black (800 mg) in absolute ethanol (ijOO m is intensively mixed under hydrogen pressure in one atmosphere before turning 630 ml of hydrogen. The reaction mixture was filtered through celite (diatomaceous earth) and concentrated in vacuo. The precipitate is dissolved in nepean twice with water, filtered and lyophilized to obtain A, 2 g of an amorphous product, 11-hydroxy- (2-phenylethyl) phosphinyl - -.- dH acetyl-o1 -proline, Al-55, p. 18.7 meganol. PRI mme R 2. 1- (Hydroxymethyl phosphinyl) acetyl - CI -prolin. And Carbonyldiimidazole (1.3 g, 0.0079 mol) was added to the cooled solution) methyl (phenylmethoxy) -phosphinyl acetic acid (1.8 g, 0.0079 mol) in acetonitrile (25 ml). The reaction mixture is stirred for 1 h at. and then at moderate temperature, left overnight. The reaction mixture is concentrated in vacuo. The residue was dissolved in ethyl acetate (250 ml), washed with bi4 potassium sulfate and dried over sodium bicarbonate; magnesium sulfate and concentrated in vacuo. The crude product is chromatographed on silica gel (Baker g, 60-200 mesh, 300 ml), washing out} 1 with a mixture of dichloromethane / ethyl acetate to give 2, k g (71) of the product 1-methyl- (phenylmethoxy) phosphinyl acetyl-cA- phenylmethyl ester Prulina, TLC, silica gel. ethyl acetate: 08 (PMA + heat-visualization. B. A mixture of 1 methyl phenylmethyl ester ((phenylmethoxy) phosphinyl 3 acetyl-oi-proline f2.3 g, 0.0052 mol) and 5% palladium on carbon black (100 mg) in absolute methanol (125 ml), was vigorously stirred under a hydrogen pressure of 1 atm until 190 ml of hydrogen were converted, and the reaction mixture was filtered through diatomaceous earth And concentrated in vacuo. The residue was dissolved in bidistillation (75 ml), filtered and lyophilized, yielding 1.1 g of amo | efnogo 1-C (hydroxymethylphosphinyl) acetyl - (i-proline. The product is again dissolved in bidistille, fi 25 ml of solution were pipetted into 25 vials and lyophilized, yielding 21, if mg of product in each vial with a total weight of 535 mg. Found C 111.01, H 6.15; "5.88; P 12.90. ch2: leonD: C .0.85;, H 6.0; N 5, 13,17. Example 3. „1-СHydroxy- (3-phenylpropyl) phosphinyl acetyl -" - proline. A. Solution of hydro-oxy (3-phenylpropyl) phosphinylacetic acids (3.5 1, 0,015 mol) and acetyl chloride (1 ml), in methanol (50 ml) on the eve of H-- - boil with reflux. The reaction mixture is then concentrated in vacuo to give 3.02 g of hydroxy- (D- "yenylpropyl) phosphinyl-acetic acid methyl ester. (Electrophoresis: 2000 V, 2Q min., 0.1 M (MY4H05," 5 cm, a single visualized with carboxyl reagent) .. B. The cooled solution () of Zbenzyl-1-p-tolyltriazene (2, b5 g, 0.012 mol) in diethyl ether (115 ml) is immediately treated with a solution of methyl hydroxy (3-methylpropyl) phosphinyl acetic acid ( 3.02 g, 0.012 mol) in ethyl acetate (10 ml). Then the reaction mixture is stirred at room temperature for an hour. Ether p The extract was extracted with hydrochloric acid and brine, dried over sodium sulfate and concentrated in vacuo.The residue was chromatographed on silica gel (si lie AR CC-7) (300 ml), washed with a mixture of hexane / ethyl acetate, to give 2 g of the product methyl ester (phenylmethoxy | - (3 phenylpropyl) phosphinyl acetic acid (TLC: silica gel, ethyl acetate / hexane (1: 1), R 0.015, UV-visualization).
    C. A solution of methyl ester (phenylmethoxy) - (3 phenylpropyl j phosphinyl acetic acid- (1.9 g, 0.0055 mol) and 1N solution of sodium hydroxide (5.6 ml) in methanol (20 ml) is stirred before at room temperature. The reaction mixture is concentrated in vacuo. The residue is dissolved in water and washed with ether. The aqueous layer is acidified with bisulfite, potassium and extracted several times with ext-25 with ethyl acetate. The combined ethyl acetate extracts are dried over magnesium sulphate and concentrated in vacuo obtaining 1.8 g of (phenylmethoxy) (3 phenylpropyl) phosphinyl 3 acetic acid s. ( electrophoresis: 2000 V, 20 min, 0.1 M + 4.5 cm, the only spot visualized with a carboxyl reagent. D. Carbonyldiimidazole (929 mg, 0.0057 mol) is dissolved in acetonitrile (140 ml), cooled in an ice bath and treated with Cphenyl-methyl (C) (3-phenylpropyl) phosphinyl with acetic acid (1.9 g, 0.0057 mol) in acetonitrile (10 ml). The mixture was stirred at 0 ° C for 1 h. The mixture is then treated with a solution of ti-proline phenylmethyl ether (1.17 g, 0.0057 mol) in acetonitrile (5 ml). The reaction mixture is stirred for 1 hour at and left at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue is dissolved in ethyl acetate, washed with potassium bisulfate and sodium bicarbonate, dried over magnesium sulfate and concentrated in vacuo. The crude chromate product is photographed on silica gel (si lie AR CC-7) (100 ml), washed out with the mixture. dichloromethane / ethyl acetate, to give 2, 3. the product is 1- (phenylmethoxy) (3-phenylpropyl) -phosphonylnyl acetyl-oi-proline phenylmethyl ester (TLC: silica gel, ethyl acetate, Rr 0.2, UV imaging).
    E. A mixture of 1- (phenylmethoxy) (3-phenylpropyl) phosphinyl-acetyl-ot-proline phenylmethyl ester (2.3 g, 0.00 mol) and 10% palladium on carbon black
    (200 mg) in absolute ethanol. (200 ml) is vigorously stirred under 1 atm of hydrogen pressure, until 200 ml of hydrogen are converted; Then the reaction mixture is filtered through diatomaceous earth and concentrated in vacuo. The cake is dissolved in bidylstilte, filtered, and lyophilized to obtain 1.4 g of amorphous 1-hydroxy- (3-phenylpropyl) phosphinylacetyl C-proline (s, 16.4, methanol). Example. 1 - (Hydroxyphenylphosphine) acetyl 3 - оС-proline.
    权利要求:
    Claims (2)
    [1]
    A. A solution of phenylphosphonic acid dimethyl ester (15.6 g, 0.09 mol) and methyl iodide (3 ml) in benzene (75 ml) is boiled under reflux for 2 h. The mixture is filtered and the filtrate is concentrated in vacuo to give a liquid residue 15.2 g (97). The NMR spectra show the presence of separate doublets, each of which is equivalent to one methyl group. The product methylphosphinic acid methyl ester is used without further purification for the following reactions. B. Trimethylsilyl bromide (15 ml, 0.1 mol) is added in portions to methyl phenylphosphonic acid phenyl ester (15.2 g, 0.1 mol) at a rate sufficient to maintain the boiling point. After that, the mixture is stirred for 1 h at a moderate temperature. The volatiles are removed in vacuo. The addition of water (10 ml) to the liquid residue (20.6 g) is accompanied by the isolation of a white solid product. The mixture is stirred rapidly at moderate temperature followed. filtering and isolating 14 g of solid. It was recrystallized from dichloromethane (80 ml) to obtain 9.9 g (72%) of methylphenylphosphinic acid with a melting point of 133-135 ° C. C. A cooled solution (0 ° C) of zyl-1-p-tolyltriazene (12.5 g, 0.056 mol) in diethyl ether (150 ml) in 45 minutes is added dropwise to a stirred suspension of methylphenylphosphonic acid 998 (8. g, 0.051 mol) in ethyl acetate (250 ml). After stirring for 3 hours at room temperature, the mixture is washed with a saturated solution of sodium bicarbonate, LIA bisulfate and brine. After drying over magnesium sulfate, the ether solution is concentrated in vacuo to obtain 1.3 g of an oily residue. It is chromatographed on silica gel, washed with ethyl acetate dichloromethane, to give 9.25 g (7) of methylphenylphosphonic acid phenylmethyl ester. LLP: silica gel, dichloromethane / ethyl acetate (1: 1),, 8, PMA + heat visualization. D. A solution of 0.033 mol of lithium diisopropyl amide is prepared by dripping N-butyl lithium (15 ml of a 2.22 solution in hexane, 0.033 mol) to diisopropylamine (1 g, 0.0 7 mol) in a cooled (0. ° С) solution hexane, (70 ml). The solvent is removed in vacuo and replaced with tetrahydrofuran (85 ml). The solution is cooled to -76 ° C. and a solution of methylphenylphosphinic acid methyl methyl phenylmethyl ester (4.1 g, 0.0166 mol, 1 equivalent) in tetrahydrofuran (50 ml) was added to it within 5 minutes. After stirring for 10 minutes, dried carbon dioxide is passed through the mixture for 30 minutes. The cooling bath is removed and the solution at room temperature is diluted with ether (1.00 ml), It is extracted with water (125 ml in two portions). The aqueous phase of CpH 10) is washed with ether and acidified with hydrochloric acid to pH 1. An oily liquid is separated from the acidified solution. It is extracted with dichloromethane (2x100 ml), washed with brine, dried (MgSO4), filtered and the solvent is removed to obtain the product phenyl (phenylmethoxy) phosphinyl acetic acid as an oily liquid (3.85 g, TJj (%). Those silica gel , dichloromethane / ethyl acetate / acetic acid (8: 1: 1), one spot R., 85 LPMA + heat visa E.Y. Carbonyldiimidazole (2.28 mg, 0.01 mol) is added to the cooled solution (0 ° C) Phenyl (phenyl-meth) si-phosphinyl acetic acid (M, 2 g, 0.01 mol) in acetonitrile (200 ml. The mixture is stirred for 1 hour and the phenylmethyl ether 10 ° C is immediately dissolved. rolina (2.85 g, 0.01t mol; in acetonitrile (20 ml K) The mixture was stirred for an additional k hours at 0 ° C, the wort was left overnight at a moderate temperature. The solvent was removed in vacuo and washed with potassium bisulfate sodium and brine. After drying (MgSO4), the solvent was removed in vacuo to give 6.7 g (according to theory) of the crude product; 8 g of the crude product obtained by the above method was chromatographed on silica gel (Baker, 60-200 mesh, 1200 ml ), washing with a mixture of dichloromethane / ethyl acetate, and get g (83%) of phenylmethyl ether 1-phenyl (phenyl toksi) phosphinyl acetyl-ct-proline. TLC: silica gel, ethyl acetate,, l6, PMA + heat visualization. F. A mixture of 1-phenylmethyl ester (phenylmethoxy), - phosphinyl-1-x-proline and 5-palladium on carbon black (100 mg) in absolute methanol is stirred under hydrogen pressure at one atmosphere until 226 ml of hydrogen is converted. The reaction mixture was filtered through diatomaceous earth and concentrated in vacuo. The residue is dissolved in bidistille, filtered and lyophilized, yielding 1.7 g (3k%) solid amorphous 1- (hydroxyphenylphosphinyl) acetyl o (.-Proline, o, (c 11.5, methanol)., L1 P and measure 5. L-CSPHyl hydroxyphosphinyl acetyl 3 o1-proline A. Replace phenyl alpha etyl bromine a i a methyl iodide gives methyl ester ethyl (phenylmethoxy) phosphinyl of acetic acid B. Change the methyl ester (2-phenylethylC-phenyl methylaminoxy-3-methylphosphine). according to the method of example 2 With methyl ethyl ester (phenylmethoxy) phosphinyl acetic acid gives ethyl (phenylmethoxy) phosphinyl acetic acid C. Replacement of (2-phenylethio) phenylmethides of phosphinyl-acetic acid by the procedure of Example 2D with ethyl (phenylmethoxy) phosphinyl acetic acid gives 1-Sethyl (phenyl methoxy) phosphinyl acetyl-o1-prolia ester. D, replacement of phenymethyl methyl ether 1 -C2-phenyl (phenylmethoxy) phosphinyl-acetyl-o-proline according to the procedure of Example 2E on phenylmethyl ether (phenylmethoxy / phosphinyl-Acetyln98-oC-proin gives to (ethylhydroxyphenyl) acetyl 3 -c / -roline. PRI me R 6. 1- (Butylhydroxyphosphinyl) acetyl-iot-proline. A. Replacing phenylmethyl bromide according to the method of Example 28 with 1-propyl iodide gives methyl ester, (butyl (phenylmeto xy) phosphinyl acetic acid. B. Replacing methyl ester (2-phenylethyl) (phenylmethoxy) phosphinyl) acetic acid according to the procedure of Example 2C with methyl ester Butyl (phenylmethoxy) phosphinyl-acetic acid gives t-butyl (phenylmethoxy) phosphinyl – acetic acid C. Replacing C2-phenylethyl (phenylmethoxy) phosphinyl-acetic acid according to the method of Example 20 with butyl (phenylmethoxy) –phosphinyl – cyclic in the –yyle –– –– –– ––––––––––––––––––––––––––––––––––––––––––––––––––– methoxy) phosphine L of acetyl-ot-Pro. D. Replacement of 1- (2-phenylethyl) (phenylmethoxy) -phos-25 phenylmethyl ester, in the case of Example 2E, phenylmethyl -ot-proline in phenylmetoxy-phenyl methyl (s6- prolinet 1- (butylhydroxyphosphinyl) 3 acetyl-oC-proline.3 (Example 1- Phenyl (2tphenylethoxy) phosphinyl 3 acetyl-o.-proline .. A. Replacement of dimethylphosphine chloride and benzyl alcohol by the method of Example 3G with methylphenylphosphinyl 35 chloride and Phenyl alcohol gives methylphenylphosphonic acid 2-phenylethyl ester. B. Replacing the methylphenylphosphonic acid phenylmethyl ester by the procedure of Example kO with the methylphenylphosphinic acid 2-phenylether gives phenyl (2-phenylethoxy) phosphinyl I acetic acid. C.Replacing Phenyl (Phenylmethoxy) PhosL | ) ynyl acetic acid according to the method of example LE on phenyl (2-phenylethoxy) -phosphinylacetic acid gives the phenylmethyl ester. 1-phenyl (2-phenyl-50 ethoxy) phosphinyl acetyl-o1-proline h. D. Replacement of the phenylmethyl ester -1-phenyl (phenylmethoxy) -phosphinyl} ace | til-6-proline. According to the method of Example iF, 1-phenyl (2-phenylethoxy) -phosphinyl-3-acetyl | -oC-proline phenylmethyl ester gives 1-phenyl (2-1e1-ethyl-phosphinyl 3-acetyl-L-proline. 55. Example 2- Phenylethyl 1-hydroxy (2-phenylethyl) phosphinyl-acetyl-N-proline A.2-Phenyl ethyl ci-proline ester is prepared from ot-proline, replacing benzyl alcohol with phenylethyl. Replacing the benzyl ester of o-proline according to the method of the example 2D on 2-.phenylethyl o-proline gives 2-phenylethyl 1- (2-phenylethyl) (phenylmethoxy) -phosphinyl acetylciproline. B. Replace phenylmethylgene ether 1- (2-phenyl) 2-phenylethyl 1-2-phenylethyl (phenylmethoxy) phosphinyl-acetyl-pC-proline 2-phenylethyl ester 2-phenyl ethyl (2-phenyl ethyl ethyl phosphinyl) (2-phenylethyl ethyl phosphinyl) (2-phenylethyl ethyl phosphinyl) (2-phenylethyl ethyl phosphinyl) - oi-proline. Formula of the invention. Method of obtaining phosphinyl-alkanoyl-prolines of general formula (T) gCO-EG-L (JOOB: Bl-P-Clf2 OR2 lower alkyl, phenyl, phenyl lower alkyl; R, hydrogen or benzyl, by reacting a new compound of the general formula (I O NP as indicated above, with phosphinyl acetic acid of the general formula 111 Rt-P-CH2- (JOOH, (W, where R is as indicated above; . R2 is benzyl, when in the presence of a condensation catalyst, 1,1-carbonyldiimidazole in acetonitrile medium and the isolation of the target product of general formula G, where R2 is benzyl.
    13 . 98819 k
    or catalytic reduction sources of information
    its hydrogen in the presence of palladium purity into account during the examination
    on soot in the environment of absolute methanol1, US Patent No. U0t6889,
    or ethanol with hydrogenacl pressure. , published, 1977.
    1 atm to get a total compound of $
    [2]
    2. US Patent No. J086338,
    Formulas (1) / where R2 in ° А ° Р ° D - 24-2, published. 1978
    类似技术:
    公开号 | 公开日 | 专利标题
    SU988194A3|1983-01-07|Process for preparing phosphonyl-alkanoyl prolines
    US4151172A|1979-04-24|Phosphonoacyl prolines and related compounds
    EP0063896B1|1985-08-14|Amino and substituted amino phosphinyl-alkanoyl compositions
    US4337201A|1982-06-29|Phosphinylalkanoyl substituted prolines
    RU2115656C1|1998-07-20|Derivatives of phosphonesuccinic acid and their pharmacologically acceptable salts and composition based on thereof
    CA1248959A|1989-01-17|Amino and substituted amino phosphinylalkanoylcompounds
    CA1227792A|1987-10-06|Phosphinylalkanoyl substituted imino acids
    AU657554B2|1995-03-16|Dialkyl |methyl phosphates as anti-inflammatory agents
    Galéotti et al.1996|A straightforward synthesis of α-amino phosphonate monoesters using BroP or TPyClU
    US4384123A|1983-05-17|Phosphinylalkanoyl substituted prolines
    US4307040A|1981-12-22|Process for producing phosphonomaleic acid esters
    IE61587B1|1994-11-16|Method for preparing phosphinic acids used in preparing ace inhibitors and intermediates produced thereby
    KR100297180B1|2001-11-30|Phospholipid derivatives and preparation methods thereof
    EP1383779B1|2004-10-13|A process for manufacture of fosinopril sodium
    US5683994A|1997-11-04|Phosphosuccinic acid derivatives, processes for the production thereof and pharmaceutical agents containing these compounds
    EP0070131A1|1983-01-19|Phosphonoalkanoylamino acids
    US5102875A|1992-04-07|Phosphonate substituted amino acids useful as antihypertensives
    KR20010067307A|2001-07-12|PROCESS FOR PRODUCING β-CAROTENE
    SU294342A1|METHOD FOR OBTAINING PROPENYLPHOSPHONE ACID or ITS DERIVATIVES
    JP3619277B2|2005-02-09|Method for producing dihydropolyprenyl monophosphate and its intermediate compound
    SU1731782A1|1992-05-07|Method of 5-dialkylaminomerhyl-1,4,6,9-tetraoxa-5-phosphaspiro[4,4]nonanes
    SAFERSTEIN1967|A STUDY OF THE CHEMISTRY OF PENTAETHOXYPHOSPHORANE
    US4282158A|1981-08-04|Process for producing α,β-unsaturated ketones
    WO1997036865A1|1997-10-09|PROCESS FOR PRODUCING INTERMEDIATE COMPOUNDS FOR THE PRODUCTION OF FACTOR Xa INHIBITORS
    FR2543553A1|1984-10-05|Phosphonamide-LACTAMES
    同族专利:
    公开号 | 公开日
    DE2942781A1|1980-04-30|
    ZA795048B|1980-09-24|
    DK148141C|1985-09-02|
    AU5130079A|1980-05-01|
    DK148141B|1985-03-18|
    LU81809A1|1980-01-25|
    BE879586A|1980-04-23|
    IE791895L|1980-04-23|
    NL7907568A|1980-04-25|
    DK445579A|1980-04-24|
    US4168267A|1979-09-18|
    IT1125558B|1986-05-14|
    FR2439790B1|1984-01-13|
    CA1133496A|1982-10-12|
    SE7908727L|1980-06-12|
    FR2439790A1|1980-05-23|
    PH13931A|1980-11-04|
    JPS5557597A|1980-04-28|
    IE49020B1|1985-07-10|
    CH645382A5|1984-09-28|
    GB2031897A|1980-04-30|
    JPS6256880B2|1987-11-27|
    IT7926704D0|1979-10-22|
    GB2031897B|1983-03-02|
    AU529134B2|1983-05-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR2288100B1|1974-10-17|1978-11-24|Poudres & Explosifs Ste Nale|
    US4046889A|1976-02-13|1977-09-06|E. R. Squibb & Sons, Inc.|Azetidine-2-carboxylic acid derivatives|
    US4151172A|1977-08-11|1979-04-24|E. R. Squibb & Sons, Inc.|Phosphonoacyl prolines and related compounds|
    US4168267A|1978-10-23|1979-09-18|E. R. Squibb & Sons, Inc.|Phosphinylalkanoyl prolines|US6458772B1|1909-10-07|2002-10-01|Medivir Ab|Prodrugs|
    US20020128301A1|1998-02-13|2002-09-12|Medivir AB|Non-nucleoside reverse transcriptase inhibitors|
    ZA794723B|1978-09-11|1980-08-27|Univ Miami|Anti-hypertensive agents|
    US4168267A|1978-10-23|1979-09-18|E. R. Squibb & Sons, Inc.|Phosphinylalkanoyl prolines|
    US4690940A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4690937A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4695577A|1979-08-14|1987-09-22|University Of Miami|Anti-hypertensive agents|
    US4698356A|1979-08-14|1987-10-06|University Of Miami|Anti-hypertensive agents|
    US4690938A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4698355A|1979-08-14|1987-10-06|University Of Miami|Anti-hypertensive agents|
    US4690939A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4734420A|1980-03-05|1988-03-29|University Of Miami|Anti-hypertensive agents|
    US4690936A|1980-03-05|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4312809A|1980-10-31|1982-01-26|E. R. Squibb & Sons, Inc.|Lactam derivatives of mercaptoacylamino acids|
    US4337201A|1980-12-04|1982-06-29|E. R. Squibb & Sons, Inc.|Phosphinylalkanoyl substituted prolines|
    US4384123A|1980-12-04|1983-05-17|E. R. Squibb & Sons, Inc.|Phosphinylalkanoyl substituted prolines|
    US4379146A|1981-02-17|1983-04-05|Merck & Co., Inc.|Substituted phosphonamides as antihypertensives|
    US4416831A|1981-04-27|1983-11-22|E. R. Squibb & Sons, Inc.|Amino and substituted amino phosphinylalkanoyl compounds|
    US4374131A|1981-04-27|1983-02-15|E. R. Squibb & Sons, Inc.|Amino and substituted amino phosphinyl-alkanoyl compounds|
    US4416833A|1981-05-04|1983-11-22|E. R. Squibb & Sons, Inc.|Substituted carbonyl phosphinyl-alkanoyl compounds|
    US4381297A|1981-05-04|1983-04-26|E. R. Squibb & Sons, Inc.|Substituted carbonyl phosphinyl-alkanoyl compounds|
    EP0070131A1|1981-07-09|1983-01-19|Analytical Research Pharmaceuticals Pty. Ltd.|Phosphonoalkanoylamino acids|
    US4432971A|1981-08-03|1984-02-21|E. R. Squibb & Sons, Inc.|Phosphonamidate compounds|
    US4432972A|1981-08-03|1984-02-21|E. R. Squibb & Sons, Inc.|Phosphonamidate compounds|
    US4371526A|1981-08-21|1983-02-01|E. R. Squibb & Sons, Inc.|Phosphinylalkanoyl substituted 4,5-dihydropyrazole-5-carboxylic acid derivatives and hypotensive method and composition|
    EP0075334A3|1981-09-25|1984-03-21|The Wellcome Foundation Limited|Pharmaceutical compounds, and preparation, formulations and use thereof|
    US4396772A|1981-11-23|1983-08-02|F. R. Squibb & Sons, Inc.|Phosphinylalkanoyl amino acids|
    US4555506A|1981-12-24|1985-11-26|E. R. Squibb & Sons, Inc.|Phosphorus containing compounds and use as hypotensives|
    US4716155A|1981-12-24|1987-12-29|E. R. Squibb & Sons, Inc.|Phosphorus containing compounds and hypotensive use thereof|
    US4452791A|1982-03-15|1984-06-05|E. R. Squibb & Sons, Inc.|Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors|
    US4560680A|1982-03-15|1985-12-24|E. R. Squibb & Sons, Inc.|Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors|
    EP0091525A3|1982-04-08|1984-02-29|Analytical Research Pharmaceuticals Pty. Ltd.|Phosphonoalkanoylamino acids|
    US4448772A|1982-04-22|1984-05-15|E. R. Squibb & Sons, Inc.|Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension|
    US4560681A|1982-04-22|1985-12-24|E. R. Squibb & Sons, Inc.|Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension|
    CA1258853A|1982-04-30|1989-08-29|Rudiger D. Haugwitz|Substituted 4-phenoxy prolines|
    US4681886A|1982-04-30|1987-07-21|E. R. Squibb & Sons, Inc.|Substituted 4-phenoxy or 4-phenylthio prolines|
    US4427665A|1982-05-19|1984-01-24|E. R. Squibb & Sons, Inc.|Phosphinylalkanoyl substituted imino acids and their use in hypotensive compositions|
    US4468519A|1982-06-14|1984-08-28|E. R. Squibb & Sons, Inc.|Esters of phosphinylalkanoyl substituted prolines|
    US4616005A|1982-06-23|1986-10-07|E. R. Squibb & Sons, Inc.|Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives|
    US4452790A|1982-06-23|1984-06-05|E. R. Squibb & Sons, Inc.|Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives|
    US4703043A|1982-06-23|1987-10-27|E. R. Squibb & Sons, Inc.|Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive|
    US4442089A|1982-07-06|1984-04-10|E. R. Squibb & Sons, Inc.|Method for treating glaucoma with topical or systemic ACE inhibitor compositions|
    US4567166A|1982-07-14|1986-01-28|E. R. Squibb & Sons, Inc.|Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension|
    US4826812A|1982-12-27|1989-05-02|Schering Corporation|Antiglaucoma agent|
    US4555579A|1983-03-24|1985-11-26|E. R. Squibb & Sons, Inc.|Dioxolenylmethyl ester prodrugs of phosphinic acid ace inhibitors|
    DE3434124C2|1983-09-19|1993-07-01|E.R. Squibb & Sons, Inc., Princeton, N.J., Us|
    IE58127B1|1983-09-19|1993-07-14|Squibb & Sons Inc|Process for preparing phosphinic acid intermediates|
    US4594199A|1983-09-19|1986-06-10|E. R. Squibb & Sons, Inc.|Method for making phosphinic acid intermediates|
    US4602092A|1983-09-19|1986-07-22|E. R. Squibb & Sons, Inc.|Method for making phosphinic acid intermediates|
    US4536501A|1984-03-30|1985-08-20|E. R. Squibb & Sons, Inc.|Substituted 4-phenoxy or 4-phenylthio prolines|
    US4625038A|1984-11-19|1986-11-25|E. R. Squibb & Sons, Inc.|-4-substituted-2-pyrrolidines-methanols|
    US4588819A|1984-11-19|1986-05-13|E. R. Squibb & Sons, Inc.|Process and intermediates for preparing trans-4-substituted-s-prolines|
    US4885380A|1986-03-13|1989-12-05|Thottathil John K|Process for preparing phosphonyloxyacyl amino acids and derivatives thereof|
    US4900860A|1986-03-13|1990-02-13|E. R. Squibb & Sons, Inc.|Process for preparing phosphonyloxyacyl amino acids|
    US4670193A|1986-05-12|1987-06-02|E. R. Squibb & Sons, Inc.|Process for preparing phosphonic acids|
    US4738850A|1986-05-27|1988-04-19|E. R. Squibb & Sons, Inc.|Controlled release formulation and method|
    JPS6435273U|1987-08-26|1989-03-03|
    US6187752B1|1988-03-07|2001-02-13|E.R. Squibb & Sons, Inc.|Method for treating schizophrenia employing an ace inhibitor|
    IL90189D0|1988-06-01|1989-12-15|Squibb & Sons Inc|Pharmaceutical compositions containing a benzazepine-type calcium channel blocker|
    CA2021409A1|1989-08-21|1991-02-22|Donald S. Karanewsky|Phosphonate substituted amino or imino acids useful as antihypertensives|
    US5189023A|1990-09-04|1993-02-23|American Cyanamid Company|Renin inhibitors|
    US6025344A|1996-06-17|2000-02-15|Guilford Pharmaceuticals Inc.|Certain dioic acid derivatives useful as NAALADase inhibitors|
    US6384022B1|1996-06-17|2002-05-07|Guilford Pharmaceuticals Inc.|Prodrugs of NAALAdase inhibitors|
    US6011021A|1996-06-17|2000-01-04|Guilford Pharmaceuticals Inc.|Methods of cancer treatment using naaladase inhibitors|
    JP2002515040A|1996-06-17|2002-05-21|ギルフォード・ファーマシューティカルズ・インコーポレイテッド|Method of treating cancer using NAALADase inhibitor|
    US6046180A|1996-06-17|2000-04-04|Guilford Pharmaceuticals Inc.|NAALADase inhibitors|
    US5977090A|1996-09-27|1999-11-02|Guilford Pharmaceuticals Inc.|Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors|
    US6071965A|1996-06-17|2000-06-06|Guilford Pharmaceuticals Inc.|Phosphinic alkanoic acid derivatives|
    US5672592A|1996-06-17|1997-09-30|Guilford Pharmaceuticals Inc.|Certain phosphonomethyl-pentanedioic acid derivatives thereof|
    US6025345A|1996-06-17|2000-02-15|Guilford Pharmaceuticals Inc.|Inhibitors of NAALADase enzyme activity|
    US5795877A|1996-12-31|1998-08-18|Guilford Pharmaceuticals Inc.|Inhibitors of NAALADase enzyme activity|
    US5863536A|1996-12-31|1999-01-26|Guilford Pharmaceuticals Inc.|Phosphoramidate derivatives|
    US5962521A|1997-04-04|1999-10-05|Guilford Pharmaceuticals Inc.|Hydroxamic acid derivatives|
    US5902817A|1997-04-09|1999-05-11|Guilford Pharmaceuticals Inc.|Certain sulfoxide and sulfone derivatives|
    US6054444A|1997-04-24|2000-04-25|Guilford Pharmaceuticals Inc.|Phosphonic acid derivatives|
    US5981209A|1997-12-04|1999-11-09|Guilford Pharmaceuticals Inc.|Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia|
    US6028216A|1997-12-31|2000-02-22|Guilford Pharmaceuticals Inc.|Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives|
    US6121252A|1998-03-30|2000-09-19|Guilford Pharmaceuticals Inc.|Phosphinic acid derivatives|
    AU770258B2|1998-07-06|2004-02-19|Eisai Inc.|Naaladase inhibitors useful as pharmaceutical compounds and compositions|
    US6265609B1|1998-07-06|2001-07-24|Guilford Pharmaceuticals Inc.|Thio-substituted pentanedioic acid derivatives|
    US6395718B1|1998-07-06|2002-05-28|Guilford Pharmaceuticals Inc.|Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors|
    US6313159B1|1999-08-20|2001-11-06|Guilford Pharmaceuticals Inc.|Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors|
    US20060135480A1|2002-12-03|2006-06-22|Enobia Pharma|Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex|
    US7459474B2|2003-06-11|2008-12-02|Bristol-Myers Squibb Company|Modulators of the glucocorticoid receptor and method|
    US7371759B2|2003-09-25|2008-05-13|Bristol-Myers Squibb Company|HMG-CoA reductase inhibitors and method|
    US7420059B2|2003-11-20|2008-09-02|Bristol-Myers Squibb Company|HMG-CoA reductase inhibitors and method|
    US7592461B2|2005-12-21|2009-09-22|Bristol-Myers Squibb Company|Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof|
    AU2007227202B2|2006-03-21|2013-08-22|Amylin Pharmaceuticals, Llc|Peptide-peptidase inhibitor conjugates and methods of using same|
    US20070238770A1|2006-04-05|2007-10-11|Bristol-Myers Squibb Company|Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations|
    EP2089355A2|2006-11-01|2009-08-19|Brystol-Myers Squibb Company|Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof|
    US8198311B2|2006-11-01|2012-06-12|Bristol-Myers Squibb Company|Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof|
    EA020466B1|2007-06-04|2014-11-28|Синерджи Фармасьютикалз Инк.|Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders|
    US8969514B2|2007-06-04|2015-03-03|Synergy Pharmaceuticals, Inc.|Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases|
    EP2195034A2|2007-09-27|2010-06-16|Amylin Pharmaceuticals, Inc.|Peptide-peptidase inhibitor conjugates and methods of making and using same|
    US7828840B2|2007-11-15|2010-11-09|Med Institute, Inc.|Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists|
    JP2011522828A|2008-06-04|2011-08-04|シナジーファーマシューティカルズインコーポレイテッド|Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders|
    CA2730603C|2008-07-16|2019-09-24|Synergy Pharmaceuticals Inc.|Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders|
    DE102008055914A1|2008-11-05|2010-05-06|Clariant International Limited|A process for the preparation of mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts by means of acroleins and their use|
    CN102177164B|2008-11-05|2015-02-11|科莱恩金融有限公司|Method for producing dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols/acroleins and use thereof|
    DE102008055916A1|2008-11-05|2010-05-06|Clariant International Limited|Process for the preparation of mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts by means of allyl alcohols and their use|
    DE102008056342A1|2008-11-07|2010-05-12|Clariant International Limited|Process for the preparation of dialkylphosphinic acids, esters and salts by means of acrylonitriles and their use|
    DE102008056339A1|2008-11-07|2010-05-12|Clariant International Limited|Process for the preparation of mono-amino-functionalized dialkylphosphinic acids, esters and salts and their use|
    DE102008056341A1|2008-11-07|2010-05-12|Clariant International Limited|Process for the preparation of mono-amino-functionalized dialkylphosphinic acids, esters and salts by means of acrylonitriles and their use|
    WO2010051893A1|2008-11-07|2010-05-14|Clariant International Ltd|Method for producing dialkylphosphinic acids and esters and salts thereof by means of acrylic acid derivatives and use thereof|
    ES2446305T3|2008-11-11|2014-03-07|Clariant FinanceLimited|Process for the preparation of dialkylphosphinic acids, their salts and mono-allyfunctionalized esters with allyl compounds and their use|
    DE102008060036A1|2008-12-02|2010-06-10|Clariant International Limited|Process for the preparation of mono-carboxy-functionalized dialkylphosphinic acids, esters and salts by means of vinyl esters of a carboxylic acid and their use|
    DE102008060035A1|2008-12-02|2010-06-10|Clariant International Limited|Process for the preparation of monohydroxy-functionalized dialkylphosphinic acids, esters and salts by means of vinyl esters of a carboxylic acid and their use|
    DE102008060535A1|2008-12-04|2010-06-10|Clariant International Limited|Process for the preparation of mono-carboxy-functionalized dialkylphosphinic acids, esters and salts by means of vinyl ethers and their use|
    DE102008063642A1|2008-12-18|2010-06-24|Clariant International Limited|Process for the preparation of monocarboxy-functionalized dialkylphosphinic acids, esters and salts by means of alkylene oxides and their use|
    DE102008063668A1|2008-12-18|2010-07-01|Clariant International Limited|Process for the preparation of alkylphosphonic acids, esters and salts by oxidation of alkylphosphonous acids and their use|
    ES2446666T3|2008-12-18|2014-03-10|Clariant FinanceLimited|Process for the preparation of ethylene-dialkyl phosphonic acids, or their esters and salts, by acetylene, and their use|
    DE102008063627A1|2008-12-18|2010-06-24|Clariant International Limited|Process for the preparation of monohydroxy-functionalized dialkylphosphinic acids, esters and salts by means of ethylene oxide and their use|
    DE102008064003A1|2008-12-19|2010-06-24|Clariant International Limited|Process for the preparation of monofunctionalized dialkylphosphinic acids, esters and salts and their use|
    DE102008064012A1|2008-12-19|2010-06-24|Clariant International Limited|Halogen-free adducts of alkylphosphonous acid derivatives and diester-forming olefins, halogen-free processes for their preparation and their use|
    US9616097B2|2010-09-15|2017-04-11|Synergy Pharmaceuticals, Inc.|Formulations of guanylate cyclase C agonists and methods of use|
    EP2970384A1|2013-03-15|2016-01-20|Synergy Pharmaceuticals Inc.|Agonists of guanylate cyclase and their uses|
    EP2968439A2|2013-03-15|2016-01-20|Synergy Pharmaceuticals Inc.|Compositions useful for the treatment of gastrointestinal disorders|
    EA201592263A1|2013-06-05|2016-05-31|Синерджи Фармасьютикалз, Инк.|ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING|
    WO2015027021A1|2013-08-22|2015-02-26|Bristol-Myers Squibb Company|Imide and acylurea derivatives as modulators of the glucocorticoid receptor|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/953,711|US4168267A|1978-10-23|1978-10-23|Phosphinylalkanoyl prolines|
    [返回顶部]